Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms of Hypertension in PCOS
NCT04327934Phase 1Terminated
- Sponsor
- Yale University
- Start
- Dec 2017
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands, Peptides, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of ganirelix and methyltestosterone in polycystic ovary syndrome (PCOS) and hypertension (HTN) (2 arms), sponsored by Yale University. Primary endpoints: Baroreflex Response to Lower Body Negative Pressure at Day 16, Free Plasma Testosterone Levels at Day 16 and 5 more. Started Dec 2017; status: terminated.
02
Drugs
ganirelixmethyltestosterone
03
Conditions
polycystic ovary syndrome (PCOS)hypertension (HTN)
Beyond the preview
Go deeper on NCT04327934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04327934.